Opko Health, Inc. Invests in Biotechnology Company Sorrento Therapeutics, Inc. Developing Human Antibody Library
Published: Jun 11, 2009
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE AMEX: OPK) announced that it has made an investment in Sorrento Therapeutics, Inc., a privately held biotechnology company based in San Diego with a proprietary platform technology for the generation of fully human monoclonal antibodies. In exchange for the investment, OPKO acquired approximately one-third of the outstanding common shares of Sorrento and received a fully-paid, exclusive license to the Sorrento antibody library for the discovery and development of therapeutic antibodies in the field of ophthalmology.